化疗和放疗可能在癌症治愈多年后引起第二原发癌（例如霍奇金病胸部放疗后的乳腺癌、治疗相关的髓系白血病）。
原始表述
سرطانات ثانوية (ثدي ولوكيميا ميلويدية) بعد سنوات من الشفاء
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
化疗和放疗可能在癌症治愈多年后引起第二原发癌（例如霍奇金病胸部放疗后的乳腺癌、治疗相关的髓系白血病）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (rule page summary/narrative)
- 出处
- https://eltayebat.com/rule/chemo-radiation/
- 归属的不确定性
- Written by archive operators; not attributed to Elawady.
- 所声称的机制
DNA damage from radiation and alkylating/topoisomerase agents
- 所声称的健康影响
Second malignancies
- 涉及人群
Cancer survivors
- Elawady 设定的地域限制
none found
科学评估
正确 – 该说法有可靠证据支持。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Secondary breast cancers and myeloid leukaemia years after cure.
2. 哪些内容可证实是正确的？
Breast-cancer RR 3.2 with >=4 Gy and 8.0 with >40 Gy after Hodgkin radiotherapy (A-CHM-06); therapy-related MDS/AML has a median survival of 8 months (A-CHM-15); tamoxifen raises endometrial cancer risk (A-CHM-08).
3. 哪些内容是错误或夸大的？
The 'heavy price' framing is not matched by absolute data: in 647,672 adult survivors, radiotherapy accounted for about 8% of second cancers in irradiated patients and 5 extra cancers per 1,000 treated by 15 years; the authors conclude most second cancers are due to other factors (A-CHM-07). Tamoxifen's benefit 'greatly outweighs' its risk (A-CHM-08).
4. 哪些内容仍不明确？
Risk under modern reduced fields and doses.
5. 哪些研究支持该说法？
A-CHM-06, A-CHM-15, A-CHM-08, I-CHM-06 (lung cancer RR 2.10 after RT); A-CHM-07 for the existence of the effect (radiotherapy-associated RR above 1 for every first-cancer site, with dose and latency gradients; 3,266 excess second solid cancers).
6. 哪些研究与该说法相矛盾？
None against the existence of treatment-related second cancers. Limiting the magnitude: A-CHM-07 (about 8% of second solid cancers in irradiated adults attributable to radiotherapy; 5 excess cancers per 1,000 treated by 15 years); I-CHM-06 (absolute lung-cancer risk about 0.3% in non-smokers).
7. 对德国和欧洲而言情况如何？
Survivorship screening programmes (e.g., early breast screening after chest radiation) exist in Europe.
8. 关于埃及的已知情况是什么？
No Egyptian data reviewed.
9. 合理的实际结论是什么？
第二原发癌是一种真实存在、但多数情况下并不常见的远期影响，这使长期随访具有必要性。
评估详情
- 证据确定性的依据
Dose-response case-control data, large registry cohort and case series agree on existence; magnitude in adults is modest.
- 来源质量
Correctly cited; magnitude context omitted.
- 地区可推广性
High.
- 个体例外情况
Higher risk after childhood/young-adult chest radiation, high doses, smoking.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: Do chemotherapy and radiotherapy cause second cancers years after treatment, and what is the absolute risk compared with the benefit?
研究问题详解 (PECO)
- 人群
- Cancer survivors treated with chemotherapy and/or radiotherapy
- 干预或暴露
- Chemotherapy (alkylating agents, topoisomerase II inhibitors, anthracyclines), radiotherapy
- 对照
- No such treatment
- 地域范围
- universal biology
- 结局指标
- Therapy-related myeloid neoplasms
- Radiation-induced solid cancers
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4 Meta分析已核查全文新增Randomised data: anthracycline caused extra acute myeloid leukaemia.
- 实际结果
- AML 12/6768 (0.18%) vs 2/6783 (0.03%); about 1 extra case per 700 women
- 方法学质量
- high (IPD meta-analysis of RCTs)
- 相关性
- direct
- 局限
- Short follow-up
Chest radiation for Hodgkin disease raises later breast-cancer risk in young women
Breast cancer after chest radiotherapy for Hodgkin disease, rising with dose and persisting for decades.
- 实际结果
- RR 3.2 (>=4 Gy) to 8.0 (>40 Gy)
- 方法学质量
- high (nested case-control)
- 相关性
- direct
- 局限
- Old high-dose techniques
Leukaemia-type cancers after breast cancer treatment
Large cohort: marrow neoplasms after adjuvant breast cancer therapy are rare but rise after 5 years.
- 实际结果
- 0.24% at 5 y, 0.48% at 10 y
- 方法学质量
- moderate (cohort)
- 相关性
- direct
- 局限
- Few events
哪些证据不支持该说法？
Only a small share of second cancers in adults is caused by radiotherapy
Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4 队列研究全文，含结构化偏倚风险评估Only a small share of second cancers in adults is attributable to radiotherapy.
- 实际结果
- 8% of second solid cancers; about 5 excess per 1000 treated by 15 years
- 方法学质量
- high (SEER cohort, full text)
- 相关性
- direct (limits the size)
- 局限
- Registry data
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Treatment-related second cancers are real; in adults they are uncommon compared with the cancers treated.
为什么有些研究权重更大
Randomised IPD data give unbiased absolute harm; registries quantify population share.
因果关系是否已确立？ 是，已确立 Dose-response, randomised comparison (AML), mechanism (DNA damage).
仍存在的不确定性
Risks beyond 15-20 years with current regimens.
合理的结论
Correct. Absolute risks: about 1-2 extra leukaemias per 1000 adjuvant breast cancer patients, and about 3-5 excess solid cancers per 1000 irradiated adults within 10-15 years; higher after childhood treatment.
这是否取决于国家？
- 一般生物学效应
- Universal biology.
- 饮食习惯
- Not relevant.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- No monitoring data relevant.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Recompute AML absolute risk and NNH; compare with NNT – 0.18% vs 0.03%; ARI 0.15%; NNH 677 (paper: about 700); NNT for recurrence 38; about 18 recurrences prevented per AML case 已重新计算
- Attributable share – 3266/42294 = 7.7% (reported 8%) 已重新计算
- HR precision – HR 6.8 (1.3-36.1) very imprecise; absolute rates per 1000 person-years (0.16-0.54) are more informative 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Therapy-related second cancers
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"marrow neoplasms" AND TITLE:"adjuvant breast cancer" | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (TITLE:"therapy-related" OR TITLE:"second malignan" OR TITLE:"second cancer" OR TITLE:"subsequent malignan") AND (TITLE:"chemotherapy" OR TITLE:"radiotherapy") AND (TITLE:"meta-analysis" OR TITLE:"cohort") AND (TITLE:"absolute" OR TITLE:"incidence") AND PUB_YEAR:[2014 TO 2026] | 双向 | 1 | |
| PubMed | 2026年10月26日 | "Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp] | 双向 | 12 |
待解决的问题
Second-cancer risk after modern radiotherapy techniques.
核查深度如何？
7 项相关研究：2 项核查了全文（其中 1 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
放疗和某些化疗药物可能在多年后引起一种新的癌症。因霍奇金淋巴瘤接受过胸部放疗的年轻女性，患乳腺癌的风险明显更高。总体而言，在成人中，每1,000名接受放疗的患者里，只有约5人会在15年内因放疗而多患一种癌症。癌症幸存者应按建议参加筛查。
与该说法相关的研究
支持该说法的研究 (4)
-
Chest radiation for Hodgkin disease raises later breast-cancer risk in young women
Travis LB et al.. JAMA 2003 · PMID 12876089 · DOI 10.1001/jama.290.4.465病例对照研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Risk was about 3 times higher with >=4 Gy and 8 times higher with >40 Gy to the breast.
Second breast cancer after HD radiotherapy
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify radiation-related breast cancer.
- 研究是如何开展的？
Nested case-control.
- 研究了多少人、动物或样本？
105 cases, 266 controls.
- 实际发现了什么？
Dose-dependent RR 3.2-8.0.
- 观察到的效应有多大？
RR 8.0 above 40 Gy.
- 研究结果对日常生活意味着什么？
Women treated with chest radiation young need breast screening.
- 该研究有哪些局限？
Old techniques, wide CIs.
- 它对 Elawady 的具体说法说明了什么？
Supports existence of second cancers.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
That Hodgkin treatment does net harm.
-
Leukaemia caused by earlier cancer treatment has a poor outlook
Smith SM et al.. Blood 2003 · PMID 12623843 · DOI 10.1182/blood-2002-11-3343病例系列 / 病例报告被 Tayebat 档案网站引用已核查摘要In 306 patients, median survival after diagnosis was 8 months.
t-MDS/AML exists and is serious
该研究是否支持这一具体说法？ 是 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Describe t-MDS/AML.
- 研究是如何开展的？
Case series.
- 研究了多少人、动物或样本？
306.
- 实际发现了什么？
Typical chromosome changes; poor survival.
- 观察到的效应有多大？
Median survival 8 months.
- 研究结果对日常生活意味着什么？
Rare but serious complication.
- 该研究有哪些局限？
No incidence data.
- 它对 Elawady 的具体说法说明了什么？
Supports existence.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
How often it happens.
-
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4Meta分析独立交叉核查已核查全文★ 关键研究Anthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.
Quantifies therapy-related AML: about one extra case per 700 women treated.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Weigh benefits and risks of anthracycline-containing chemotherapy
- 研究是如何开展的？
Pooled individual data from randomised trials
- 研究了多少人、动物或样本？
18,103 women in the main comparison; about 100,000 overall
- 实际发现了什么？
Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%
- 观察到的效应有多大？
10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline
- 研究结果对日常生活意味着什么？
For every leukaemia caused, roughly 18 recurrences are prevented in this data set
- 该研究有哪些局限？
Short follow-up for heart effects; high-risk heart patients often excluded
- 它对 Elawady 的具体说法说明了什么？
Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot quantify heart failure 15-20 years after treatment
-
Leukaemia-type cancers after breast cancer treatment
Wolff AC et al.. J Clin Oncol 2015 · PMID 25534386 · DOI 10.1200/JCO.2013.54.6119队列研究独立交叉核查已核查摘要★ 关键研究About 5 in 1000 treated women developed a marrow cancer within 10 years.
Confirms therapy-related marrow neoplasms; absolute risk about 0.5% at 10 years.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure risk of marrow cancers after treatment
- 研究是如何开展的？
Cohort of 20,063 patients
- 研究了多少人、动物或样本？
US academic centres
- 实际发现了什么？
Low but real risk that keeps rising after 5 years
- 观察到的效应有多大？
0.24% at 5 y, 0.48% at 10 y
- 研究结果对日常生活意味着什么？
Rare, but a reason for follow-up
- 该研究有哪些局限？
Few events
- 它对 Elawady 的具体说法说明了什么？
Supports existence of second cancers; shows they are rare
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot show harm outweighs benefit
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (0)
该组中没有研究。
结果不一或不明确的研究 (3)
-
Only a small share of second cancers in adults is caused by radiotherapy
Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究About 5 extra cancers per 1,000 treated patients within 15 years; 8% of second cancers in irradiated patients.
Small attributable fraction (8%; 5/1000 at 15 y)
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate radiotherapy-attributable second cancers.
- 研究是如何开展的？
SEER cohort.
- 研究了多少人、动物或样本？
647,672 survivors.
- 实际发现了什么？
8% attributable; 5/1000 by 15 years.
- 观察到的效应有多大？
RR 1.08-1.43.
- 研究结果对日常生活意味着什么？
The risk is real but small compared with the benefit of cure.
- 该研究有哪些局限？
No randomisation; no data on smoking, chemotherapy or doses; treatments before 2003.
- 它对 Elawady 的具体说法说明了什么？
Limits the 'heavy price' framing.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Risk for an individual patient.
-
Tamoxifen raises the small risk of uterine cancer but prevents far more breast-cancer events
Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527随机对照试验被 Tayebat 档案网站引用已核查摘要Uterine cancer about 1.6 vs 0.2 per 1,000 women per year; 38% fewer recurrence-type events.
Endometrial cancer excess; net benefit
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess second cancers under tamoxifen.
- 研究是如何开展的？
RCT vs placebo.
- 研究了多少人、动物或样本？
2,843 + 1,220.
- 实际发现了什么？
RR 7.5 endometrial cancer; benefit outweighs.
- 观察到的效应有多大？
1.6 vs 0.2/1000/year.
- 研究结果对日常生活意味着什么？
Report abnormal bleeding during tamoxifen; continue therapy.
- 该研究有哪些局限？
Few events; data-integrity issue.
- 它对 Elawady 的具体说法说明了什么？
Mixed.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That tamoxifen is net harmful.
-
With modern techniques, radiotherapy's heart and lung risks are small for non-smokers
Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722Meta分析独立交叉核查已核查摘要★ 关键研究About 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.
Lung cancer risk small in non-smokers
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate absolute RT risks.
- 研究是如何开展的？
Dose review + IPD meta-analysis.
- 研究了多少人、动物或样本？
40,781 women.
- 实际发现了什么？
Small absolute risks; smoking key.
- 观察到的效应有多大？
Cardiac mortality RR 1.30.
- 研究结果对日常生活意味着什么？
Stop smoking before/after radiotherapy.
- 该研究有哪些局限？
Smoking modelled.
- 它对 Elawady 的具体说法说明了什么？
Puts Darby in perspective.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual dose-specific risk.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Survivorship screening programmes (e.g., early breast screening after chest radiation) exist in Europe.
埃及
No Egyptian data reviewed.
在我的国家适用什么？
一般科学评估
正确 治疗相关的第二原发癌确实存在；在成人中，与被治愈的癌症相比，它们并不常见。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.. Travis LB et al.. JAMA 2003 · PMID 12876089 · DOI 10.1001/jama.290.4.465
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.. Smith SM et al.. Blood 2003 · PMID 12623843 · DOI 10.1182/blood-2002-11-3343
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
- Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.. Wolff AC et al.. J Clin Oncol 2015 · PMID 25534386 · DOI 10.1200/JCO.2013.54.6119
- Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.. Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4
- Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.. Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722